Sanofi To Sell Its Doliprane Production Subsidiary

Sanofi To Sell Its Doliprane Production Subsidiary

Sanofi's Doliprane medecine boxes pictured in Camps-la-source, France on September 24, 2024. While Servier gave up on selling Biogaran at the beginning of September, the project to sell Opella, Sanofi’s healthcare subsidiary, which notably houses the iconic little yellow box, is still underway. Following the first indicative offers submitted in July, the takeover candidates had until 23 September to submit their firm takeover bids. Photo by Laurent Coust/ABACAPRESS.COM

  • Product Code
  • ILEA003352647
  • Registered date
  • 2024/9/24 00:00:00
  • Credit
  • Abaca Press / Kyodo News Images
  • Media source
  • Coust Laurent/ABACA
  • Media size
  • 5298 × 3532 pixel
  • Resolution
  • 300 dpi
  • Deployment size
  • 2.75(MB)*
  • Special instruction

*File size when opened in Photoshop, etc.

Similar Images & Videos
    Government Demands Guarantees For Doliprane Production In France

    Government Demands Guarantees For Doliprane Production In France

    Illustrations Doliprane on October 15, 2024. The French laboratory Sanofi announced on October 4 that it wanted to sell part of its subsidiary Opella, which produces generic drugs such as Doliprane, to an American fund, the American investment fund CD-R. On Wednesday, the French Health Minister called for guarantees that Doliprane would be “produced in France”, that pharmacies would receive “normal supplies” and that “sufficient stocks” would be available. Photo by Jean Pierre Nguyen Van Hai Barbier/ABACAPRESS.COM
      Government Demands Guarantees For Doliprane Production In France

      Government Demands Guarantees For Doliprane Production In France

      Illustrations Doliprane on October 15, 2024. The French laboratory Sanofi announced on October 4 that it wanted to sell part of its subsidiary Opella, which produces generic drugs such as Doliprane, to an American fund, the American investment fund CD-R. On Wednesday, the French Health Minister called for guarantees that Doliprane would be “produced in France”, that pharmacies would receive “normal supplies” and that “sufficient stocks” would be available. Photo by Jean Pierre Nguyen Van Hai Barbier/ABACAPRESS.COM
        Government Demands Guarantees For Doliprane Production In France

        Government Demands Guarantees For Doliprane Production In France

        Illustrations Doliprane on October 15, 2024. The French laboratory Sanofi announced on October 4 that it wanted to sell part of its subsidiary Opella, which produces generic drugs such as Doliprane, to an American fund, the American investment fund CD-R. On Wednesday, the French Health Minister called for guarantees that Doliprane would be “produced in France”, that pharmacies would receive “normal supplies” and that “sufficient stocks” would be available. Photo by Jean Pierre Nguyen Van Hai Barbier/ABACAPRESS.COM
          Government Demands Guarantees For Doliprane Production In France

          Government Demands Guarantees For Doliprane Production In France

          Illustrations Doliprane on October 15, 2024. The French laboratory Sanofi announced on October 4 that it wanted to sell part of its subsidiary Opella, which produces generic drugs such as Doliprane, to an American fund, the American investment fund CD-R. On Wednesday, the French Health Minister called for guarantees that Doliprane would be “produced in France”, that pharmacies would receive “normal supplies” and that “sufficient stocks” would be available. Photo by Jean Pierre Nguyen Van Hai Barbier/ABACAPRESS.COM
            Government Demands Guarantees For Doliprane Production In France

            Government Demands Guarantees For Doliprane Production In France

            Illustrations Doliprane on October 15, 2024. The French laboratory Sanofi announced on October 4 that it wanted to sell part of its subsidiary Opella, which produces generic drugs such as Doliprane, to an American fund, the American investment fund CD-R. On Wednesday, the French Health Minister called for guarantees that Doliprane would be “produced in France”, that pharmacies would receive “normal supplies” and that “sufficient stocks” would be available. Photo by Jean Pierre Nguyen Van Hai Barbier/ABACAPRESS.COM
              Government Demands Guarantees For Doliprane Production In France

              Government Demands Guarantees For Doliprane Production In France

              Illustrations Doliprane on October 15, 2024. The French laboratory Sanofi announced on October 4 that it wanted to sell part of its subsidiary Opella, which produces generic drugs such as Doliprane, to an American fund, the American investment fund CD-R. On Wednesday, the French Health Minister called for guarantees that Doliprane would be “produced in France”, that pharmacies would receive “normal supplies” and that “sufficient stocks” would be available. Photo by Jean Pierre Nguyen Van Hai Barbier/ABACAPRESS.COM
                Government Demands Guarantees For Doliprane Production In France

                Government Demands Guarantees For Doliprane Production In France

                Illustrations Doliprane on October 15, 2024. The French laboratory Sanofi announced on October 4 that it wanted to sell part of its subsidiary Opella, which produces generic drugs such as Doliprane, to an American fund, the American investment fund CD-R. On Wednesday, the French Health Minister called for guarantees that Doliprane would be “produced in France”, that pharmacies would receive “normal supplies” and that “sufficient stocks” would be available. Photo by Jean Pierre Nguyen Van Hai Barbier/ABACAPRESS.COM
                  Government Demands Guarantees For Doliprane Production In France

                  Government Demands Guarantees For Doliprane Production In France

                  Illustrations Doliprane on October 15, 2024. The French laboratory Sanofi announced on October 4 that it wanted to sell part of its subsidiary Opella, which produces generic drugs such as Doliprane, to an American fund, the American investment fund CD-R. On Wednesday, the French Health Minister called for guarantees that Doliprane would be “produced in France”, that pharmacies would receive “normal supplies” and that “sufficient stocks” would be available. Photo by Jean Pierre Nguyen Van Hai Barbier/ABACAPRESS.COM
                    Government Demands Guarantees For Doliprane Production In France

                    Government Demands Guarantees For Doliprane Production In France

                    Illustrations Doliprane on October 15, 2024. The French laboratory Sanofi announced on October 4 that it wanted to sell part of its subsidiary Opella, which produces generic drugs such as Doliprane, to an American fund, the American investment fund CD-R. On Wednesday, the French Health Minister called for guarantees that Doliprane would be “produced in France”, that pharmacies would receive “normal supplies” and that “sufficient stocks” would be available. Photo by Jean Pierre Nguyen Van Hai Barbier/ABACAPRESS.COM
                      Government Demands Guarantees For Doliprane Production In France

                      Government Demands Guarantees For Doliprane Production In France

                      Illustrations Doliprane on October 15, 2024. The French laboratory Sanofi announced on October 4 that it wanted to sell part of its subsidiary Opella, which produces generic drugs such as Doliprane, to an American fund, the American investment fund CD-R. On Wednesday, the French Health Minister called for guarantees that Doliprane would be “produced in France”, that pharmacies would receive “normal supplies” and that “sufficient stocks” would be available. Photo by Jean Pierre Nguyen Van Hai Barbier/ABACAPRESS.COM